These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 17687166)

  • 1. Ovarian cancer and the battle of the specialists.
    McGuire WP
    J Clin Oncol; 2007 Aug; 25(23):3554-5; author reply 3557-8. PubMed ID: 17687166
    [No Abstract]   [Full Text] [Related]  

  • 2. Chemotherapy administration for ovarian cancer by gynecologic oncologists and medical oncologists.
    Berchuck A
    J Clin Oncol; 2007 Aug; 25(23):3552; author reply 3557-8. PubMed ID: 17687164
    [No Abstract]   [Full Text] [Related]  

  • 3. Type of oncology specialist and treatment-related outcomes in ovarian cancer.
    Hoffman MA; Iqbal U
    J Clin Oncol; 2007 Aug; 25(23):3553; author reply 3557-8. PubMed ID: 17687165
    [No Abstract]   [Full Text] [Related]  

  • 4. Does ovarian cancer treatment and survival differ by the specialty providing chemotherapy?
    Markman M
    J Clin Oncol; 2007 Aug; 25(23):3554; author reply 3557-8. PubMed ID: 17687167
    [No Abstract]   [Full Text] [Related]  

  • 5. More than a name.
    Blank SV; Curtin JP
    J Clin Oncol; 2007 Aug; 25(23):3551; author reply 3557-8. PubMed ID: 17687163
    [No Abstract]   [Full Text] [Related]  

  • 6. Gynecologic oncology or medical oncology: what's in a name?
    Cannistra SA
    J Clin Oncol; 2007 Apr; 25(10):1157-9. PubMed ID: 17401003
    [No Abstract]   [Full Text] [Related]  

  • 7. Chemotherapy in epithelial ovarian cancer.
    Pignata S; Cannella L; Leopardo D; Pisano C; Bruni GS; Facchini G
    Cancer Lett; 2011 Apr; 303(2):73-83. PubMed ID: 21353386
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does ovarian cancer treatment and survival differ by the specialty providing chemotherapy?
    Silber JH; Rosenbaum PR; Polsky D; Ross RN; Even-Shoshan O; Schwartz JS; Armstrong KA; Randall TC
    J Clin Oncol; 2007 Apr; 25(10):1169-75. PubMed ID: 17401005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Key clinical trials in gynaecological oncology.
    Morrison J; Kehoe S
    Eur J Surg Oncol; 2006 Oct; 32(8):887-91. PubMed ID: 16677796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advanced cancer of the ovary: intraperitoneal chemotherapy as a new therapeutical option.
    Fiorentini G; Filippeschi M; Turrisi G; Mambrini A; Giannessi PG; D'Alessandro M; Rossi S; Dentico P; Guadagni S; Cantore M; Madrigali A
    In Vivo; 2009; 23(2):317-21. PubMed ID: 19414421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant chemotherapy in advanced ovarian cancer: what kind of evidence is needed to convince US gynaecological oncologists?
    Vergote I; Amant F; Leunen K
    Gynecol Oncol; 2010 Oct; 119(1):1-2. PubMed ID: 20833283
    [No Abstract]   [Full Text] [Related]  

  • 12. Intraperitoneal chemotherapy in ovarian cancer remains experimental.
    Gore M; du Bois A; Vergote I
    J Clin Oncol; 2006 Oct; 24(28):4528-30. PubMed ID: 17008689
    [No Abstract]   [Full Text] [Related]  

  • 13. Ovarian cancer: is dose intensity dead?
    Ozols RF
    J Clin Oncol; 2007 Sep; 25(27):4157-8. PubMed ID: 17698802
    [No Abstract]   [Full Text] [Related]  

  • 14. Why overall survival should not be the sole valid primary endpoint of phase 3 ovarian cancer chemotherapy trials.
    Markman M
    Gynecol Oncol; 2007 Aug; 106(2):279-81. PubMed ID: 17662376
    [No Abstract]   [Full Text] [Related]  

  • 15. "Therapeutic intent" in phase 1 oncology trials: a justifiable objective.
    Markman M
    Arch Intern Med; 2006 Jul; 166(14):1446-8. PubMed ID: 16864753
    [No Abstract]   [Full Text] [Related]  

  • 16. [Oncology pharmacy specialists in oncology].
    Ikesue H; Oishi R
    Gan To Kagaku Ryoho; 2008 Apr; 35(4):578-82. PubMed ID: 18408426
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Current topic of intraperitoneal infusions for treatment of ovarian cancer].
    Fujiwara K
    Gan To Kagaku Ryoho; 2008 Feb; 35(2):224-227. PubMed ID: 18372511
    [No Abstract]   [Full Text] [Related]  

  • 18. Treatment of ovarian carcinoma: possibilities for progress.
    Bagley CM; Young RC; Canellos GP; DeVita VT
    N Engl J Med; 1972 Oct; 287(17):856-62. PubMed ID: 4561148
    [No Abstract]   [Full Text] [Related]  

  • 19. Systemic chemotherapy for uterine carcinoma: metastatic and adjuvant.
    Fleming GF
    J Clin Oncol; 2007 Jul; 25(20):2983-90. PubMed ID: 17617530
    [No Abstract]   [Full Text] [Related]  

  • 20. Intraperitoneal chemotherapy in the treatment of ovarian cancer.
    Kavanagh JJ
    J Surg Oncol; 2007 Dec; 96(7):541-2. PubMed ID: 17654524
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.